Precision Pathology Podcast (P³)

In this episode, we discuss the recent publication in Nature Cancer by Jason L. Vassy et al. on building a personalized genomic risk model to enhance precision in prostate cancer screening. Guest Kara Maxwell, MD, PhD, from the University of Pennsylvania, explains how the PCARE test combines a polygenic risk score with genetic ancestry and family history to guide PSA decisions in clinical care. Yo...

Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. Given that T2DM and obesity are associated with a higher risk of cancer, the potential of GLP1RAs use to reduce cancer risk is of great interest. Professor Edoardo Mannucci from the University of Florence, Italy, discusses his recent publication in Nature Reviews Clinical Oncol...

Ben Stanger, MD, Hannah Weiss Professor of Oncology at the University of Pennsylvania, discusses his team's groundbreaking study on the use of KRAS-targeted small molecules to eliminate pancreatic cancer precursor lesions (PanIN) in a preclinical mouse model. The tremendous clinical implications of intercepting cancer development using novel pharmacologic agents are highlighted. View Dr. Stanger's...

In this episode, Dr. Sydney Shaffer shares her expertise on cutting-edge technologies, including single-cell and spatial transcriptomics, and their significance for understanding cancer biology. The guest discusses these tools in the context of her recent Nature Communications publication ( https://doi.org/10.1038/s41467-025-66302-w ), which provides a single-cell view of cell dynamics in Barrett’...

Join Dr. George Netto as he discusses with Professor Felix Sahm, an international expert from Heidelberg University, his team's innovative multi-center study on intraoperative molecular profiling of central nervous system tumors (CNS). Learn how rapid methylation profiling could change the landscape of diagnostics and management of brain neoplasms. Don't miss this enlightening discussion! #Neuropa...

Join Dr. George Netto and Dr. Matija Snuderl of Langone Health at NY University as they discuss the significance of TERT promoter mutations in meningiomas and their implications for patient prognosis. This conversation sheds light on the need for reevaluation of molecular biomarkers in the grading of Meningiomas. #Meningioma #MolecularDiagnostics #TERTPromoter #Pathology #CancerResearch #TumorGrad...

In this episode, I discuss with Dr. Salgado, Co-Chair of the International Immuno-Oncology Biomarkers Working Group, his editorial ( https://doi.org/10.1016/j.ccell.2025.03.020 ) on the recent Cancer Cell study by Ding Ma et al, presenting a predictive AI model for HER2-targeting ADC efficacy, incorporating immune system components, hormone receptor status, clinical staging, and HER2+ cell proport...

Introducing P³ Podcast Welcome to P³, our new podcast series on Precision Pathology, created and hosted by Dr. George J. Netto, the Simon Flexner Professor and  Chair of Pathology and Laboratory Medicine at the University of Pennsylvania in Philadelphia, PA. In each episode, Dr. Netto will share his perspective on the latest discoveries in precision medicine through informal conversations with acc...

Rapid and accurate assessment of EGFR mutations in lung adenocarcinoma is critical for the management of NSCLC patients. PCR-based assays provide rapid results but with reduced accuracy compared with next-generation sequencing and can exhaust the increasingly valuable small amount of biopsy tissue available for predictive biomarkers. Computational biomarkers Leveraging modern foundation models may...